• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

    4.130 +0.230 (+5.90%)
    Streaming Delayed Price Updated: 4:00 PM EST, Jan 7, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 5,800,443
    Open 3.940
    Bid (Size) 4.100 (500)
    Ask (Size) 4.200 (800)
    Prev. Close 3.900
    Today's Range 3.851 - 4.200
    52wk Range 1.891 - 6.515
    Shares Outstanding 287,686,199
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    AbCellera and Bruker Reach Global Settlement of Patent Litigation
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026
    From AbCellera Biologics Inc.
    Via Business Wire

    Performance

    YTD
    +20.4%
    +20.4%
    1 Month
    +15.0%
    +15.0%
    3 Month
    -28.4%
    -28.4%
    6 Month
    +6.2%
    +6.2%
    1 Year
    +24.8%
    +24.8%

    More News

    Read More
    News headline image
    AbCellera Appoints Dr. Stephen Quake to its Board of Directors
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 7, 2025 ↗
    Via Benzinga
    News headline image
    AI Stocks Extend Selloff, Nasdaq 100 Eyes Worst Week Since April: What's Moving Markets Friday? ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    AbCellera Biologics Inc (NASDAQ:ABCL) Reports Mixed Q3 2025 Results with Revenue Beat and Wider Loss ↗
    Via Chartmill
    News headline image
    AbCellera Reports Q3 2025 Business Results
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera to Participate at Upcoming Investor Conferences in November and December 2025
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    Stock Market Today: Dow Futures Slip, Nasdaq Rises Amid Mixed Trade—AngioDynamics, Entero Therapeutics, Fermi In Focus ↗
    Via Benzinga
    Topics Stocks
    News headline image
    AI Stocks Slide Again, Bitcoin Dips Near $100,000: What's Moving Markets Thursday? ↗
    Via Benzinga
    Topics Artificial Intelligence
    News headline image
    Why Did AbCellera's Stock Jump Over 7% After Hours? ↗
    Via Benzinga
    News headline image
    AbCellera to Report Third Quarter 2025 Financial Results on November 6, 2025
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    AbCellera Doses First Participants in a Phase 1 Clinical Trial of ABCL575
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    10 Health Care Stocks With Whale Alerts In Today's Session ↗
    Via Benzinga
    News headline image
    AbCellera to Participate at Upcoming Investor Conferences in September
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    Expert Outlook: AbCellera Biologics Through The Eyes Of 4 Analysts ↗
    Via Benzinga
    News headline image
    12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
    Via Benzinga
    News headline image
    AbCellera Biologics (ABCL) Q2 2025 Earnings Call Transcript ↗
    Via The Motley Fool
    Topics Earnings
    News headline image
    Curious about the stocks that are showing activity after the closing bell on Thursday? ↗
    Via Chartmill
    News headline image
    AbCellera Reports Q2 2025 Business Results & First Participants Dosed in a Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    Galaxy Digital, Blaize Holdings, Verizon And Other Big Stocks Moving Higher On Monday ↗
    Via Benzinga
    News headline image
    AbCellera to Report Second Quarter 2025 Financial Results on August 7, 2025
    From AbCellera Biologics Inc.
    Via Business Wire
    News headline image
    Why AbCellera Biologics Stock Raced Nearly 6% Higher Today ↗
    Via The Motley Fool

    Frequently Asked Questions

    Is AbCellera Biologics Inc. - Common Shares publicly traded?
    Yes, AbCellera Biologics Inc. - Common Shares is publicly traded.
    What exchange does AbCellera Biologics Inc. - Common Shares trade on?
    AbCellera Biologics Inc. - Common Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for AbCellera Biologics Inc. - Common Shares?
    The ticker symbol for AbCellera Biologics Inc. - Common Shares is ABCL on the Nasdaq Stock Market
    What is the current price of AbCellera Biologics Inc. - Common Shares?
    The current price of AbCellera Biologics Inc. - Common Shares is 4.130
    When was AbCellera Biologics Inc. - Common Shares last traded?
    The last trade of AbCellera Biologics Inc. - Common Shares was at 01/07/26 04:00 PM ET
    What is the market capitalization of AbCellera Biologics Inc. - Common Shares?
    The market capitalization of AbCellera Biologics Inc. - Common Shares is 1.19B
    How many shares of AbCellera Biologics Inc. - Common Shares are outstanding?
    AbCellera Biologics Inc. - Common Shares has 1B shares outstanding.
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.